How much did Antisense Therapeutics achieve in EBIT for the current year?
In the current year, Antisense Therapeutics has achieved an EBIT of -16.51 M AUD.
Antisense Therapeutics EBIT 2024
Antisense Therapeutics EBIT
-16.51 M AUD
Ticker
ANP.AX
ISIN
AU000000ANP4
WKN
982306
In 2024, Antisense Therapeutics's EBIT was -16.51 M AUD, a 45.08% increase from the -11.38 M AUD EBIT recorded in the previous year.
The Antisense Therapeutics EBIT history
| YEAR | EBIT (undefined AUD) |
|---|---|
| 2027e | -15,536.08 |
| 2026e | -9,746.5 |
| 2025e | -17,018.5 |
| 2024e | -16,510.47 |
| 2023 | -11,380.21 |
| 2022 | -5,799.15 |
| 2021 | -8,101.34 |
| 2020 | -5,997.43 |
| 2019 | -2,940.28 |
| 2018 | -2,322.17 |
| 2017 | -2,747.35 |
| 2016 | -2,544.71 |
| 2015 | 732.76 |
| 2014 | -3,030 |
| 2013 | -2,470 |
| 2012 | -1,800 |
| 2011 | -1,810 |
| 2010 | -3,410 |
| 2009 | -3,910 |
| 2008 | -440 |
| 2007 | -4,840 |
| 2006 | -5,460 |
| 2005 | -6,270 |
| 2004 | -4,980 |
Antisense Therapeutics Revenue, EBIT, Net Income AU000000ANP4 · 982306
3 years
5 years
10 years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Antisense Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Antisense Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Antisense Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Antisense Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Antisense Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Antisense Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Antisense Therapeutics’s growth potential.
Antisense Therapeutics Revenue, Profit, and EBIT History
| Date | Antisense Therapeutics Revenue | Antisense Therapeutics EBIT | Antisense Therapeutics Net Income |
|---|---|---|---|
| 2027e | 551,250 undefined | -15.54 M undefined | -20 M undefined |
| 2026e | 3.43 M undefined | -9.75 M undefined | -10.84 M undefined |
| 2025e | 2.53 M undefined | -17.02 M undefined | -228.85 M undefined |
| 2024e | 2.66 M undefined | -16.51 M undefined | -20.94 M undefined |
| 2023 | 384,920 undefined | -11.38 M undefined | -11.38 M undefined |
| 2022 | 34,180 undefined | -5.8 M undefined | -5.81 M undefined |
| 2021 | 4,180 undefined | -8.1 M undefined | -8.06 M undefined |
| 2020 | 30,530 undefined | -6 M undefined | -5.91 M undefined |
| 2019 | 66,170 undefined | -2.94 M undefined | -2.94 M undefined |
| 2018 | 25,550 undefined | -2.32 M undefined | -2.33 M undefined |
| 2017 | 140,170 undefined | -2.75 M undefined | -2.75 M undefined |
| 2016 | 1.13 M undefined | -2.54 M undefined | -2.51 M undefined |
| 2015 | 3.92 M undefined | 732,760 undefined | 706,920 undefined |
| 2014 | 80,000 undefined | -3.03 M undefined | -3.01 M undefined |
| 2013 | 200,000 undefined | -2.47 M undefined | -2.45 M undefined |
| 2012 | 100,000 undefined | -1.8 M undefined | -1.8 M undefined |
| 2011 | 90,000 undefined | -1.81 M undefined | -1.81 M undefined |
| 2010 | 100,000 undefined | -3.41 M undefined | -3.42 M undefined |
| 2009 | 260,000 undefined | -3.91 M undefined | -2.65 M undefined |
| 2008 | 6.82 M undefined | -440,000 undefined | -2.14 M undefined |
| 2007 | 490,000 undefined | -4.84 M undefined | -4.84 M undefined |
| 2006 | 410,000 undefined | -5.46 M undefined | -5.46 M undefined |
| 2005 | 850,000 undefined | -6.27 M undefined | -6.27 M undefined |
| 2004 | 1.34 M undefined | -4.98 M undefined | -4.61 M undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2004 | 1.34 M AUD | -4.98 M AUD | -4.61 M AUD |
| 2005 | 850,000 AUD | -6.27 M AUD | -6.27 M AUD |
| 2006 | 410,000 AUD | -5.46 M AUD | -5.46 M AUD |
| 2007 | 490,000 AUD | -4.84 M AUD | -4.84 M AUD |
| 2008 | 6.82 M AUD | -440,000 AUD | -2.14 M AUD |
| 2009 | 260,000 AUD | -3.91 M AUD | -2.65 M AUD |
| 2010 | 100,000 AUD | -3.41 M AUD | -3.42 M AUD |
| 2011 | 90,000 AUD | -1.81 M AUD | -1.81 M AUD |
| 2012 | 100,000 AUD | -1.8 M AUD | -1.8 M AUD |
| 2013 | 200,000 AUD | -2.47 M AUD | -2.45 M AUD |
| 2014 | 80,000 AUD | -3.03 M AUD | -3.01 M AUD |
| 2015 | 3.92 M AUD | 732,760 AUD | 706,920 AUD |
| 2016 | 1.13 M AUD | -2.54 M AUD | -2.51 M AUD |
| 2017 | 140,170 AUD | -2.75 M AUD | -2.75 M AUD |
| 2018 | 25,550 AUD | -2.32 M AUD | -2.33 M AUD |
| 2019 | 66,170 AUD | -2.94 M AUD | -2.94 M AUD |
| 2020 | 30,530 AUD | -6 M AUD | -5.91 M AUD |
| 2021 | 4,180 AUD | -8.1 M AUD | -8.06 M AUD |
| 2022 | 34,180 AUD | -5.8 M AUD | -5.81 M AUD |
| 2023 | 384,920 AUD | -11.38 M AUD | -11.38 M AUD |
| 2024e | 2.66 M AUD | -16.51 M AUD | -20.94 M AUD |
| 2025e | 2.53 M AUD | -17.02 M AUD | -228.85 M AUD |
| 2026e | 3.43 M AUD | -9.75 M AUD | -10.84 M AUD |
| 2027e | 551,250 AUD | -15.54 M AUD | -20 M AUD |
Antisense Therapeutics stock margins AU000000ANP4 · 982306
The Antisense Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Antisense Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Antisense Therapeutics.
3 years
5 years
10 years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Antisense Therapeutics's sales revenue. A higher gross margin percentage indicates that the Antisense Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Antisense Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Antisense Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Antisense Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Antisense Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Antisense Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Antisense Therapeutics Margin History
| Antisense Therapeutics Gross margin | Antisense Therapeutics Profit margin | Antisense Therapeutics EBIT margin | Antisense Therapeutics Profit margin |
|---|---|---|---|
| 2027e | 401.9 % | -2,818.34 % | -3,627.24 % |
| 2026e | 401.9 % | -283.91 % | -315.63 % |
| 2025e | 401.9 % | -674 % | -9,063.41 % |
| 2024e | 401.9 % | -620.69 % | -787.33 % |
| 2023 | 401.9 % | -2,956.51 % | -2,956.41 % |
| 2022 | 5,014.63 % | -16,966.5 % | -17,003.54 % |
| 2021 | 11,196.17 % | -193,811.96 % | -192,838.28 % |
| 2020 | 401.9 % | -19,644.38 % | -19,352.11 % |
| 2019 | 401.9 % | -4,443.52 % | -4,449.9 % |
| 2018 | 401.9 % | -9,088.73 % | -9,123.37 % |
| 2017 | 401.9 % | -1,960.01 % | -1,965.33 % |
| 2016 | 401.9 % | -224.78 % | -222.1 % |
| 2015 | 401.9 % | 18.71 % | 18.05 % |
| 2014 | 401.9 % | -3,787.5 % | -3,762.5 % |
| 2013 | 401.9 % | -1,235 % | -1,225 % |
| 2012 | 401.9 % | -1,800 % | -1,800 % |
| 2011 | 401.9 % | -2,011.11 % | -2,011.11 % |
| 2010 | 401.9 % | -3,410 % | -3,420 % |
| 2009 | 401.9 % | -1,503.85 % | -1,019.23 % |
| 2008 | 401.9 % | -6.45 % | -31.38 % |
| 2007 | 401.9 % | -987.76 % | -987.76 % |
| 2006 | 401.9 % | -1,331.71 % | -1,331.71 % |
| 2005 | 401.9 % | -737.65 % | -737.65 % |
| 2004 | 401.9 % | -371.64 % | -344.03 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2004 | 401.9 % | -371.64 % | -344.03 % |
| 2005 | 401.9 % | -737.65 % | -737.65 % |
| 2006 | 401.9 % | -1,331.71 % | -1,331.71 % |
| 2007 | 401.9 % | -987.76 % | -987.76 % |
| 2008 | 401.9 % | -6.45 % | -31.38 % |
| 2009 | 401.9 % | -1,503.85 % | -1,019.23 % |
| 2010 | 401.9 % | -3,410 % | -3,420 % |
| 2011 | 401.9 % | -2,011.11 % | -2,011.11 % |
| 2012 | 401.9 % | -1,800 % | -1,800 % |
| 2013 | 401.9 % | -1,235 % | -1,225 % |
| 2014 | 401.9 % | -3,787.5 % | -3,762.5 % |
| 2015 | 401.9 % | 18.71 % | 18.05 % |
| 2016 | 401.9 % | -224.78 % | -222.1 % |
| 2017 | 401.9 % | -1,960.01 % | -1,965.33 % |
| 2018 | 401.9 % | -9,088.73 % | -9,123.37 % |
| 2019 | 401.9 % | -4,443.52 % | -4,449.9 % |
| 2020 | 401.9 % | -19,644.38 % | -19,352.11 % |
| 2021 | 11,196.17 % | -193,811.96 % | -192,838.28 % |
| 2022 | 5,014.63 % | -16,966.5 % | -17,003.54 % |
| 2023 | 401.9 % | -2,956.51 % | -2,956.41 % |
| 2024e | 401.9 % | -620.69 % | -787.33 % |
| 2025e | 401.9 % | -674 % | -9,063.41 % |
| 2026e | 401.9 % | -283.91 % | -315.63 % |
| 2027e | 401.9 % | -2,818.34 % | -3,627.24 % |
Antisense Therapeutics Aktienanalyse
What does Antisense Therapeutics do?
Antisense Therapeutics Ltd is an Australian biopharmaceutical company that focuses on developing novel therapies for rare and severe diseases. The company was founded in 1987 and is headquartered in Melbourne. Antisense Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.EBIT Details
Analyzing Antisense Therapeutics's EBIT
Antisense Therapeutics's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.
Year-to-Year Comparison
A yearly comparison of Antisense Therapeutics's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.
Impact on Investments
Antisense Therapeutics's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.
Interpreting EBIT Fluctuations
Fluctuations in Antisense Therapeutics’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.
Frequently Asked Questions about Antisense Therapeutics Stock
What is EBIT?
EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Antisense Therapeutics.
How has the EBIT of Antisense Therapeutics developed in recent years?
The EBIT of Antisense Therapeutics has increased by 45.081% increased compared to the previous year.
What does EBIT mean for investors?
EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.
Why is EBIT an important indicator for investors?
Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.
Why do EBIT values fluctuate?
EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.
What role does tax burden play in EBIT?
Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.
How is EBIT presented in the balance sheet of the company Antisense Therapeutics?
The EBIT of Antisense Therapeutics is listed in the income statement.
Can EBIT be used as a single indicator for evaluating a company?
EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.
Why is EBIT not equal to net profit?
The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.
How much dividend does Antisense Therapeutics pay?
Over the past 12 months, Antisense Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Antisense Therapeutics is expected to pay a dividend of 0 AUD.
What is the dividend yield of Antisense Therapeutics?
The current dividend yield of Antisense Therapeutics is .
When does Antisense Therapeutics pay dividends?
Antisense Therapeutics pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Antisense Therapeutics?
Antisense Therapeutics paid dividends every year for the past 0 years.
What is the dividend of Antisense Therapeutics?
For the upcoming 12 months, dividends amounting to 0 AUD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Antisense Therapeutics located?
Antisense Therapeutics is assigned to the 'Health' sector.
Wann musste ich die Aktien von Antisense Therapeutics kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Antisense Therapeutics from 6/26/2024 amounting to 0 AUD, you needed to have the stock in your portfolio before the ex-date on 6/26/2024.
When did Antisense Therapeutics pay the last dividend?
The last dividend was paid out on 6/26/2024.
What was the dividend of Antisense Therapeutics in the year 2023?
In the year 2023, Antisense Therapeutics distributed 0 AUD as dividends.
In which currency does Antisense Therapeutics pay out the dividend?
The dividends of Antisense Therapeutics are distributed in AUD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Antisense Therapeutics
Our stock analysis for Antisense Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Antisense Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
- Antisense Therapeutics Revenue
- Antisense Therapeutics Net Income
- Antisense Therapeutics P/E
- Antisense Therapeutics P/S
- Antisense Therapeutics EBIT
- Antisense Therapeutics Dividend
- Antisense Therapeutics Stocks
- Antisense Therapeutics Market capitalization
- Antisense Therapeutics Debt
- Antisense Therapeutics Liabilities
- Antisense Therapeutics Equity
- Antisense Therapeutics AAQS
- Antisense Therapeutics Employees
- Antisense Therapeutics ROE
- Antisense Therapeutics ROA
- Antisense Therapeutics ROCE
